European Inspections Present New Challenges to U.S. Manufacturers
This article was originally published in The Gold Sheet
Executive Summary
DANGEROUS CONVERSATIONS are at the heart of a European inspections process that fundamentally differs from FDA’s approach. There is little guidance about the process, which is geared toward reaching conclusions rather than building a case. The European Union inspectors are more experienced, less by-the-book, more likely to chat with workers on the shop floor, experts say. Their inspections tend to be quicker, and can vary by their country of origin
You may also be interested in...
Emergent Suspends COVID-19 Vaccine API Manufacturing As US FDA Inspects Bayview Plant
After discovery of viral vector cross-contamination, AstraZeneca quit, J&J took control and the FDA launched inspection.
Industry ICH Proposal Would Limit International Regulatory Oversight Of Manufacturing Models
The focus would be on high-impact changes to high-impact models under approach advocated by BioPhorum, IQ Consortium and PPAR.
Remote Site Visits Will Help US FDA Keep Reviews On Track As Pandemic Constraints Continue
Guidance discusses what are generically called virtual inspections, but which the agency terms “remote interactive evaluations.” As site inspections remain constrained by the pandemic, remote interactive evaluations “should help FDA operate within normal timeframes,” the document says.